$4.10
0.74% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Geron Corporation Stock price

$4.10
+0.04 0.99% 1M
+0.62 17.82% 6M
+1.99 94.31% YTD
+2.19 114.66% 1Y
+2.56 166.23% 3Y
+2.74 201.47% 5Y
+0.51 14.21% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.03 0.74%
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Key metrics

Market capitalization $2.48b
Enterprise Value $2.22b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 75.44
P/S ratio (TTM) P/S ratio 84.07
P/B ratio (TTM) P/B ratio 8.46
Revenue growth (TTM) Revenue growth 9,199.68%
Revenue (TTM) Revenue $29.48m
EBIT (operating result TTM) EBIT $-207.97m
Free Cash Flow (TTM) Free Cash Flow $-216.50m
Cash position $341.63m
EPS (TTM) EPS $-0.32
P/E forward negative
P/S forward 27.71
EV/Sales forward 24.87
Short interest 12.71%
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Geron Corporation forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Geron Corporation forecast:

Buy
100%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
29 29
9,113% 9,113%
100%
- Direct Costs 1.62 1.62
-
5%
28 28
-
95%
- Selling and Administrative Expenses 121 121
104% 104%
412%
- Research and Development Expense 113 113
6% 6%
384%
-207 -207
15% 15%
-702%
- Depreciation and Amortization 1.15 1.15
13% 13%
4%
EBIT (Operating Income) EBIT -208 -208
15% 15%
-705%
Net Profit -201 -201
15% 15%
-682%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Neutral
Business Wire
5 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 1,017,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on November 20...
Positive
Seeking Alpha
5 days ago
Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat. Analysts are bullish, with H.C. Wainwright, Leerink, and Goldman Sachs projecting significant sales growth and maintaining high price targets for Geron. Favorable funding deals with Royalty Pharma and Pharmakon Advisors provide $375mn...
Neutral
Business Wire
15 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization ...
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO John Scarlett
Employees 141
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today